Showing 2781-2790 of 5689 results for "".
- First Subject Enrolled in Trial to Confirm Safety and Efficacy of TearCare Device for Dry Eyehttps://modernod.com/news/first-subject-enrolled-in-large-trial-to-confirm-safety-and-efficacy-of-dry-eye-treatment-device-tearcare/2476650/Sight Sciences announced the first subject has been enrolled in OLYMPIA, a US pivotal trial to further assess the safety and efficacy of TearCare for patients with dry eye disease. TearCare is a wearable, personalized, open-eye technology that delivers regu
- Three-Year Clinical Trial Results Support Iluvien Launch in Europe for Prevention of Relapse in Recurrent Noninfectious Uveitis Affecting the Posterior Segmenthttps://modernod.com/news/three-year-clinical-trial-results-support-iluvien-launch-in-europe-for-prevention-of-relapse-in-recurrent-noninfectious-uveitis-affecting-the-posterior-segment/2476635/Alimera Sciences announced 3-year followup data from the phase 3 clinical trial for Iluvien 190 micrograms intravitreal implant in applicator for the prevention of relapse in recurrent noninfectious uveitis affecting the posterior segment of the eye (NIPU). The data will support the company’s pla
- Goldman Sachs Unit to Buy 575 Optometry Practices in $2.7 Billion Dealhttps://modernod.com/news/report-goldman-sachs-unit-to-buy-capital-vision-services-in-2-7-billion-deal/2476625/In one of the largest optometry deals to date, the merchant-banking division of Goldman Sachs Group (West Street Capital Partners VII) announced that it is buying Capital Vision Services, which operates 575 optometry practices, from private-equity firm Altas Partners LP and Canadian pension fund
- OptiKira Awarded Phase 2 SBIR Grant to Support Development of Retinitis Pigmentosa Treatmenthttps://modernod.com/news/optikira-awarded-phase-2-sbir-grant-to-support-development-of-retinitis-pigmentosa-treatment/2476622/OptiKira announced that it was awarded a phase 2 Small Business Innovation Research (SBIR) grant to support continued development of a therapy that has the potential to preserve vision in patients with retinitis pigmentosa (RP). The $1.6M grant will be used to advance one or more of OptiKira’s mo
- Seniors With Vision Loss Experience Discrimination, Depressionhttps://modernod.com/news/seniors-with-vision-loss-experience-discrimination-depression/2476623/Seniors with declining vision are more likely than peers with good eyesight to experience discrimination as well as depression that may result from this bias, a new study from the UK suggests, according to a Reuters report. After s
- The Maze of Vision Loss and Depression in Older Adultshttps://modernod.com/news/the-maze-of-vision-loss-and-depression-in-older-adults/2476619/“The association between vision loss and depression is a complex conundrum,” Alan R. Morse, JD, PhD, President and CEO of Lighthouse Guild, said in a commentary on the challenges of vision loss and depression in older adults, published today in JAMA O
- WaveOptics and Pegatron Demonstrate AiR Glasses Prototypehttps://modernod.com/news/waveoptics-and-pegatron-demonstrate-air-glasses-prototype/2476618/WaveOptics, a designer and manufacturer of diffractive waveguides, and Pegatron, a manufacturing service provider, are demonstrating a prototype AiR glasses at both AWE and Pegatron Day. WaveOptics and Pegatron have also formed a strategic partnership to develop AR wearables for the rapidl
- Vision Loss Linked With Anxiety, Depression – and Vice Versahttps://modernod.com/news/vision-loss-linked-with-anxiety-depression-and-vice-versa/2476616/Older adults with impaired vision are more likely to have symptoms of anxiety and depression, and older adults with symptoms of anxiety or depression are more likely to develop vision impairment, according to findings from the U.S. National Health and Aging Trends Study, as
- Ocular Therapeutix Announces Receipt of C-Code and Pass-Through Payment Status for Dextenzahttps://modernod.com/news/ocular-therapeutix-announces-receipt-of-c-code-and-pass-through-payment-status-for-dextenza/2476614/Ocular Therapeutix announced that the Centers for Medicare and Medicaid Services (CMS) has approved transitional pass-through payment status and established a new reimbursement code for Dextenza (dexamethasone ophthalmic insert). The code, C9048, is scheduled to become effective July 1, 2019.
- NTC Grants Further License and Distribution Rights to Santen for Its Fixed Combination Dexamethasone With Levofloxacinhttps://modernod.com/news/ntc-grants-further-license-and-distribution-rights-to-santen-for-its-fixed-combination-dexamethasone-with-levofloxacin-in-south-east-asia/2476602/Italy-based NTC Srl and Santen Pharmaceutical announced an extension of their original agreement for Europe granting NTC’s license and distribution rights of levofloxacin+dexamethasone fixed combination eye drops to Santen. The countries covered by the exten